Table 1.

Baseline characteristics of patients at ICU admission

	All population (n = 177)		Clinical failure (n = 52)		Clinical cure (n = 125)		p
	Nb	Results	Nb	Results	Nb	Results
Gender (male)	177	134 (75.7%)	52	42 (80.8%)	125	92 (73.6%)	0.311
Age (years)	177	64 (50–70)	52	65 (50–70)	125	64 (50–71)	0.928
Past medical history
Hospitalization during the last 12 months	175	72 (41.1%)	52	21 (40.4%)	123	51 (41.5%)	0.895
Hospitalization delay (months)	74	1 (1–2)	21	1 (1–3)	53	1 (1–1)	0.03
ATBs during the last 3 months	166	31 (18.7%)	49	9 (18.4%)	117	22 (18.8%)	0.948
Immunosuppression	177	61 (34.5%)	52	14 (26.9%)	125	47 (37.6%)	0.173
Corticosteroids	61	50 (82%)	14	12 (85.7%)	47	38 (80.9%)	0.678
Immunosuppressive therapy	61	10 (16.4%)	14	2 (14.3%)	47	8 (17%)	0.808
Hemopathy	61	1 (1.6%)	14	0 (0%)	47	1 (2.1%)	0.582
Extravascular device	177	7 (4%)	52	2 (3.8%)	125	5 (4%)	0.962
Endovascular device	177	40 (22.6%)	52	9 (17.3%)	125	31 (24.8%)	0.278
Diabetes mellitus	177	46 (26%)	52	17 (32.7%)	125	29 (23.2%)	0.19
McCabe score	176	1 (0–2)	51	1 (0–2)	125	1 (0–2)	0.933
Delay from hospitalization to ICU (days)	174	0 (0–1)	50	0 (0–1)	124	0 (0–0)	0.408
ICU
Surgery at admission	176	57 (32.4%)	52	16 (30.8%)	124	41 (33.1%)	0.767
Infection at admission	175	69 (39.4%)	51	17 (33.3%)	124	52 (41.9%)	0.29
SAPS II score	140	37 (27–49)	42	37 (27–54)	98	37.5 (27–49)	0.747
SOFA score at admission	131	6 (3–8)	41	5 (3–8)	90	7 (3–8)	0.972

Hospitalization delay is the delay between the last hospitalization and this hospitalization. Intravascular devices include all implanted medical devices with an intravascular portion. Extravascular devices include all medical devices implanted without contact with blood

ATBs: antibiotics; ICU: Intensive Care Unit; Nb: number of available values for the data; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment